Kanda Hirotsugu, Liu Shue, Kanao Megumi, Yi Hyun, Iida Takafumi, Huang Wan, Kunisawa Takayuki, Lubarsky David A, Hao Shuanglin
Department of Anesthesiology, University of Miami Miller School of Medicine, Miami, Florida 33136.
Department of Anesthesiology and Critical Care Medicine, Asahikawa Medical University, Japan 078-8510.
Transl Perioper Pain Med. 2017;2(4):24-32.
While effective antiretroviral treatment makes human immunodeficiency virus (HIV)-related death decreased dramatically, neuropathic pain becomes one of the most common complications in patients with HIV/acquired immunodeficiency syndrome (AIDS). The exact mechanisms of HIV-related neuropathic pain are not well understood yet, and no effective therapy is for HIV-pain. Evidence has shown that proinflammatory factors (e.g., tumor necrosis factor alpha (TNFα)) released from glia, are critical to contributing to chronic pain. Preclinical studies have demonstrated that non-replicating herpes simplex virus (HSV)-based vector expressing human enkephalin reduces inflammatory pain, neuropathic pain, or cancer pain in animal models. In this review, we describe recent advances in the use of HSV-based gene transfer for the treatment of HIV pain, with a special focus on the use of HSV-mediated soluble TNF receptor I (neutralizing TNFα in function) in HIV neuropathic pain model.
虽然有效的抗逆转录病毒治疗使人类免疫缺陷病毒（HIV）相关死亡人数大幅下降，但神经性疼痛却成为HIV/获得性免疫缺陷综合征（AIDS）患者最常见的并发症之一。HIV相关神经性疼痛的确切机制尚未完全明确，且尚无针对HIV疼痛的有效治疗方法。有证据表明，神经胶质细胞释放的促炎因子（如肿瘤坏死因子α（TNFα））在慢性疼痛的形成中起关键作用。临床前研究表明，表达人脑啡肽的非复制型单纯疱疹病毒（HSV）载体可减轻动物模型中的炎性疼痛、神经性疼痛或癌痛。在本综述中，我们描述了基于HSV的基因转移在治疗HIV疼痛方面的最新进展，特别关注在HIV神经性疼痛模型中使用HSV介导的可溶性TNF受体I（功能上可中和TNFα）的情况。
